Medline Poised to Sustain High-Single Digit Organic Growth, BofA Says

MT Newswires Live01-13

Medline (MDLN) is poised to sustain high-single digit organic growth in the longer term, driven by market share gains and strong demand for medical-surgical products, BofA Securities said in a Monday note.

The brokerage said the company has ramped up its merger and acquisition transactions and this is expected to continue and further accelerate its growth.

Medline grew its total revenue 14% from 2012 through 2025, driven by 5% market growth, 7.5% organic share gains and 1.5% from M&A. Its scale and manufacturing capabilities allow it to sell private-label products cheaper than competitors, supporting share gains.

Tariffs are expected to hit earnings before interest, taxes, depreciation and amortization by roughly $525 million through 2026. The investment firm sees this as a one-time impact and said the growth is expected to accelerate in 2027 and beyond.

BofA initiated coverage on Medline with a buy rating and $50 price objective.

Shares of Medline were up 4.5% in recent trading.

Price: 42.00, Change: +1.48, Percent Change: +3.65

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603054274?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 00:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603054274","market":"sg","top_or_hot":-1,"title":"Medline Poised to Sustain High-Single Digit Organic Growth, BofA Says","media":"MT Newswires Live","content":"<html><body><p> Medline (MDLN) is poised to sustain high-single digit organic growth in the longer term, driven by market share gains and strong demand for medical-surgical products, BofA Securities said in a Monday note.</p><p>The brokerage said the company has ramped up its merger and acquisition transactions and this is expected to continue and further accelerate its growth.</p><p>Medline grew its total revenue 14% from 2012 through 2025, driven by 5% market growth, 7.5% organic share gains and 1.5% from M&amp;A. Its scale and manufacturing capabilities allow it to sell private-label products cheaper than competitors, supporting share gains.</p><p>Tariffs are expected to hit earnings before interest, taxes, depreciation and amortization by roughly $525 million through 2026. The investment firm sees this as a one-time impact and said the growth is expected to accelerate in 2027 and beyond.</p><p>BofA initiated coverage on Medline with a buy rating and $50 price objective.</p><p>Shares of Medline were up 4.5% in recent trading.</p><p>Price: 42.00, Change: +1.48, Percent Change: +3.65</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medline Poised to Sustain High-Single Digit Organic Growth, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedline Poised to Sustain High-Single Digit Organic Growth, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-13 00:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Medline (MDLN) is poised to sustain high-single digit organic growth in the longer term, driven by market share gains and strong demand for medical-surgical products, BofA Securities said in a Monday note.</p><p>The brokerage said the company has ramped up its merger and acquisition transactions and this is expected to continue and further accelerate its growth.</p><p>Medline grew its total revenue 14% from 2012 through 2025, driven by 5% market growth, 7.5% organic share gains and 1.5% from M&amp;A. Its scale and manufacturing capabilities allow it to sell private-label products cheaper than competitors, supporting share gains.</p><p>Tariffs are expected to hit earnings before interest, taxes, depreciation and amortization by roughly $525 million through 2026. The investment firm sees this as a one-time impact and said the growth is expected to accelerate in 2027 and beyond.</p><p>BofA initiated coverage on Medline with a buy rating and $50 price objective.</p><p>Shares of Medline were up 4.5% in recent trading.</p><p>Price: 42.00, Change: +1.48, Percent Change: +3.65</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603054274","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603054274","pubTimestamp":1768236941,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Medline  is poised to sustain high-single digit organic growth in the longer term, driven by market share gains and strong demand for medical-surgical products, BofA Securities said in a Monday note.The brokerage said the company has ramped up its merger and acquisition transactions and this is expected to continue and further accelerate its growth.Medline grew its total revenue 14% from 2012 through 2025, driven by 5% market growth, 7.5% organic share gains and 1.5% from M&A. Its scale and manufacturing capabilities allow it to sell private-label products cheaper than competitors, supporting share gains.Tariffs are expected to hit earnings before interest, taxes, depreciation and amortization by roughly $525 million through 2026. The investment firm sees this as a one-time impact and said the growth is expected to accelerate in 2027 and beyond.BofA initiated coverage on Medline with a buy rating and $50 price objective.Shares of Medline were up 4.5% in recent trading.Price: 42.00, Cha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","MDLN":"Medline Inc"},"translate_title":"美国银行表示，Medline有望维持高个位数有机增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDLN":1.5},"content_text":"Medline (MDLN) is poised to sustain high-single digit organic growth in the longer term, driven by market share gains and strong demand for medical-surgical products, BofA Securities said in a Monday note.The brokerage said the company has ramped up its merger and acquisition transactions and this is expected to continue and further accelerate its growth.Medline grew its total revenue 14% from 2012 through 2025, driven by 5% market growth, 7.5% organic share gains and 1.5% from M&A. Its scale and manufacturing capabilities allow it to sell private-label products cheaper than competitors, supporting share gains.Tariffs are expected to hit earnings before interest, taxes, depreciation and amortization by roughly $525 million through 2026. The investment firm sees this as a one-time impact and said the growth is expected to accelerate in 2027 and beyond.BofA initiated coverage on Medline with a buy rating and $50 price objective.Shares of Medline were up 4.5% in recent trading.Price: 42.00, Change: +1.48, Percent Change: +3.65","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603054274","isCrawlerRequest":true}